Alofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection. The therapy is being developed in Crohn’s disease for the treatment of complex perianal fistulas which show an inadequate response to at least one conventional or biologic therapy, including antibiotics, immunosuppressants, or anti-tumor necrosis factor (TNF) agents.
LIST OF FIGURES
13 Figure 11: Datamonitor Healthcare’s drug assessment summary of Cimzia in Crohn’s disease
15 Figure 40: Top treatment challenges in Crohn’s disease
18 Figure 41: Summary of future usage of biosimilar infliximab at one year and three years post-launch
LIST OF TABLES
5 Table 1: Alofisel drug profile
7 Table 2: Alofisel Phase III data in Crohn’s disease
10 Table 3: Alofisel Phase III trial in Crohn’s disease
12 Table 4: Alofisel Phase I/II data in Crohn’s disease
19 Table 5: Alofisel sales for Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726